{"protocolSection": {"identificationModule": {"nctId": "NCT01685840", "orgStudyIdInfo": {"id": "Pro00033097"}, "organization": {"fullName": "Duke University", "class": "OTHER"}, "briefTitle": "Guiding Evidence Based Therapy Using Biomarker Intensified Treatment", "officialTitle": "Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.", "acronym": "GUIDE-IT"}, "statusModule": {"statusVerifiedDate": "2017-11", "overallStatus": "TERMINATED", "whyStopped": "Project was stopped due to futility", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2016-09-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-09-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-09-12", "studyFirstSubmitQcDate": "2012-09-12", "studyFirstPostDateStruct": {"date": "2012-09-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-09-20", "resultsFirstSubmitQcDate": "2017-11-10", "resultsFirstPostDateStruct": {"date": "2017-12-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-11-10", "lastUpdatePostDateStruct": {"date": "2017-12-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Duke University", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objective is to determine the efficacy of a strategy of biomarker-guided therapy compared with usual care in high risk patients with left ventricular systolic dysfunction.", "detailedDescription": "Heart failure is a common disorder in which the heart cannot pump enough blood to meet the needs of the rest of the body. Common symptoms of heart failure include shortness of breath, swelling, and fatigue. Standard treatment for heart failure include diuretics to control fluid, as well as drugs called \"neurohormonal antagonists\" (such as beta-blockers and ACE-inhibitors) that help the heart work more efficiently and prevent worsening of heart function. Typically, doctors adjust these medicines based on their clinical judgment about what doses and combination will work best for you. We are testing whether the use of a blood test called NT-proBNP (which measures a hormone released by the heart) can help doctors do a better job of adjusting these heart failure medicines over time than clinical judgment alone."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 894, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Usual Care", "type": "EXPERIMENTAL", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.", "interventionNames": ["Other: Usual Care"]}, {"label": "Biomarker-Guided Care", "type": "EXPERIMENTAL", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.", "interventionNames": ["Device: Biomarker-guided care NT-proBNP"]}], "interventions": [{"type": "OTHER", "name": "Usual Care", "description": "Usual Care", "armGroupLabels": ["Usual Care"]}, {"type": "DEVICE", "name": "Biomarker-guided care NT-proBNP", "description": "Device: NT-proBNP", "armGroupLabels": ["Biomarker-Guided Care"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "CV Death or Heart Failure Hospitalization", "description": "Composite of First Heart Failure Hospitalization or Cardiovascular Mortality", "timeFrame": "24 Months"}], "secondaryOutcomes": [{"measure": "All-cause Mortality", "description": "All-cause mortality by treatment arm", "timeFrame": "24 months"}, {"measure": "Cumulative Morbidity", "description": "Days alive and not hospitalized for CV reasons", "timeFrame": "24 months"}, {"measure": "CV Death", "description": "CV death by treatment arm", "timeFrame": "24 months"}, {"measure": "Number of Hospitalizations for First Heart Failure", "description": "First Heart Failure Hospitalization", "timeFrame": "24 months"}, {"measure": "Number of Hospitalizations for Recurrent Heart Failure", "description": "Recurrent Heart Failure Hospitalization", "timeFrame": "24 months"}, {"measure": "Percentage of Patients With Moderate to Severe Depression", "description": "Percentage of patients with moderate to severe depression as measured by the Center for Epidemiologic Studies Depression Scale (CES-D).\n\nCES-D is a 20-item scale measuring general depression. Scores range from 0-60, with higher scores indicating greater general depression. Moderate to severe depression is indicated by a score of 11 or higher.", "timeFrame": "Baseline, 3,6, 12 and 24 months"}, {"measure": "Duke Activity Status Index (DASI)", "description": "The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity).", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "EQ-5D Health Index", "description": "The EQ-5D measures the subjects health status in 5 categories (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and totals them into 1 score, from -0.59 (worst) to 1 (best).", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "EQ-5D Visual Analog Scale", "description": "The EQ-5D VAS records participants self-rated health status on a vertical (0-100) scale with higher scores indicating higher Health-Related Quality of Life, where 0 = worst imaginable health state and 100 = best imaginable health state.", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Score", "description": "This KCCQ overall score represents the mean of the following 4 scores: Physical Limitation, Total Symptom, Quality of Life, and Social Limitation. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.", "timeFrame": "Baseline, 3, 6,12 and 24 months"}, {"measure": "Short Form-36 (SF-36) General Health Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "Short Form-36 (SF-36) Mental Health Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "Short Form-36 (SF-36) Social Functioning Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "Short Form-36 (SF-36) Physiological Functioning Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "Short Form-36 (SF-36) Vitality Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "timeFrame": "Baseline, 3, 6, 12 and 24 months"}, {"measure": "Resource Utilization", "description": "Observed Resource Use", "timeFrame": "24 months"}, {"measure": "Resource Utilization Cost", "description": "Observed Hospital-Based Cost.", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 years or older\n* Most recent LVEF to be \u2264 40% by any method within 12 months of randomization.\n* High risk heart failure as defined by the following criteria:\n\nA Heart Failure Event in the prior 12 months, defined as any one of the following:\n\n* HF Hospitalization\n* Treatment in the Emergency Department (or equivalent) for Heart Failure\n* Outpatient treatment for heart failure with intravenous diuretics\n\nAND\n\n* NT-proBNP greater than 2000 pg/mL or BNP greater than 400 pg/mL at any time during the 30 days prior to randomization\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Acute coronary syndrome (clinical diagnosis) or cardiac revascularization procedure within 30 days\n* Cardiac resynchronization therapy (CRT) within prior 3 months or current plan to implant CRT device\n* Active myocarditis, Hypertrophic obstructive cardiomyopathy, pericarditis, or restrictive cardiomyopathy\n* Severe stenotic valvular disease\n* Anticipated heart transplantation or ventricular assist device within 12 months\n* Chronic inotropic therapy\n* Complex congenital heart disease\n* End stage renal disease with renal replacement therapy\n* Non cardiac terminal illness with expected survival less than 12 months\n* Women who are pregnant or planning to become pregnant\n* Inability to comply with planned study procedures\n* Enrollment or planned enrollment in another clinical trial", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Michael Felker, MD", "affiliation": "Duke University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "The Heart Center PC", "city": "Huntsville", "state": "Alabama", "zip": "35801", "country": "United States", "geoPoint": {"lat": 34.7304, "lon": -86.58594}}, {"facility": "Sutter Memorial Hospital", "city": "Sacramento", "state": "California", "zip": "95819", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "University of California San Diego Medical Center", "city": "San Diego", "state": "California", "zip": "92037", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Yale University School of Medicine", "city": "New Haven", "state": "Connecticut", "zip": "06510", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Holy Cross Medical Group", "city": "Coral Springs", "state": "Florida", "zip": "33065", "country": "United States", "geoPoint": {"lat": 26.27119, "lon": -80.2706}}, {"facility": "Holy Cross Hospital", "city": "Fort Lauderdale", "state": "Florida", "zip": "33308", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "University Cardiology Associates, LLC", "city": "Augusta", "state": "Georgia", "zip": "30901", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "Fox Valley Clinical Research Center, LLC", "city": "Aurora", "state": "Illinois", "zip": "60504", "country": "United States", "geoPoint": {"lat": 41.76058, "lon": -88.32007}}, {"facility": "Krannert Institute of Cardiology", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "University of Maryland", "city": "Baltimore", "state": "Maryland", "zip": "21201", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Metropolitan Cardiovascular Consultants", "city": "Beltsville", "state": "Maryland", "zip": "20705", "country": "United States", "geoPoint": {"lat": 39.03483, "lon": -76.90747}}, {"facility": "Massachusetts General Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Beth Israel Medical Center", "city": "Boston", "state": "Massachusetts", "zip": "02215", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Pentucket Medical Associates", "city": "Haverhill", "state": "Massachusetts", "zip": "01830", "country": "United States", "geoPoint": {"lat": 42.7762, "lon": -71.07728}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Washington University School of Medicine", "city": "San Luis", "state": "Missouri", "zip": "63112", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Dartmouth Hitchcock Medical Center", "city": "Lebanon", "state": "New Hampshire", "zip": "03756", "country": "United States", "geoPoint": {"lat": 43.64229, "lon": -72.25176}}, {"facility": "Cardiovascular Associates of the Delaware Valley", "city": "Cherry Hill", "state": "New Jersey", "zip": "08034", "country": "United States", "geoPoint": {"lat": 39.93484, "lon": -75.03073}}, {"facility": "Robert Wood Johnson University Hospital", "city": "New Brunswick", "state": "New Jersey", "zip": "08903", "country": "United States", "geoPoint": {"lat": 40.48622, "lon": -74.45182}}, {"facility": "Cardiovascular Associates of the Delaware Valley", "city": "Sewell", "state": "New Jersey", "zip": "08080", "country": "United States", "geoPoint": {"lat": 39.7665, "lon": -75.14434}}, {"facility": "Bronx-Lebanon Hospital Center", "city": "Bronx", "state": "New York", "zip": "10457", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Jacobi Medical Center", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Albert Einstein University Hospital", "city": "Bronx", "state": "New York", "zip": "10467", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "New York Methodist Hospital", "city": "Brooklyn", "state": "New York", "zip": "11215", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Saratoga Cardiology Associates", "city": "Saratoga Springs", "state": "New York", "zip": "12866", "country": "United States", "geoPoint": {"lat": 43.08313, "lon": -73.78457}}, {"facility": "University of North Carolina at Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Novant Health Heart and Vascular Institute", "city": "Charlotte", "state": "North Carolina", "zip": "28204", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "LeBauer Cardiovascular Research Foundation", "city": "Greensboro", "state": "North Carolina", "zip": "27401", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "University of Cincinnati Medical Center", "city": "Cincinnati", "state": "Ohio", "zip": "45267", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Cleveland Clinic Foundation", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Capitol Area Research, LLC", "city": "Camp Hill", "state": "Pennsylvania", "zip": "17011", "country": "United States", "geoPoint": {"lat": 40.23981, "lon": -76.91997}}, {"facility": "Drexel University College of Medicine", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19102", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Thomas Jefferson University Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Allegheny-Singer Research Institute", "city": "Pittsburg", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "AnMed Health Medical Center", "city": "Anderson", "state": "South Carolina", "zip": "29621", "country": "United States", "geoPoint": {"lat": 34.50344, "lon": -82.65013}}, {"facility": "University of Texas Southwestern Medical Center Dallas", "city": "Dallas", "state": "Texas", "zip": "75390", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Intermountain Medical Center", "city": "Murray", "state": "Utah", "zip": "84157", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Cardiovascular Associates, Ltd.", "city": "Chesapeake", "state": "Virginia", "zip": "23320", "country": "United States", "geoPoint": {"lat": 36.81904, "lon": -76.27494}}, {"facility": "Foothills Medical Centre", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "University of Alberta Hospital", "city": "Edmonton", "state": "Alberta", "zip": "T6G 2B7", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "Vancouver General Hospital", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Saint Paul's Hospital", "city": "Vancouver", "state": "British Columbia", "zip": "V6Z 1Y6", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Hamilton Health Sciences", "city": "Hamilton", "state": "Ontario", "zip": "L8L 2X2", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "St. Michaels Hospital", "city": "Toronto", "state": "Ontario", "zip": "M5B 1W8", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}]}, "referencesModule": {"references": [{"pmid": "34784657", "type": "DERIVED", "citation": "Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ, Ahmad T, Adams K, Pina IL, Cooper LS, Januzzi JL, Leifer ES, Mark D, O'Connor CM, Felker GM. The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC Heart Fail. 2022 Feb;9(1):77-86. doi: 10.1002/ehf2.13692. Epub 2021 Nov 16."}, {"pmid": "34166799", "type": "DERIVED", "citation": "Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. J Card Fail. 2021 Dec;27(12):1359-1366. doi: 10.1016/j.cardfail.2021.06.008. Epub 2021 Jun 22."}, {"pmid": "33992564", "type": "DERIVED", "citation": "Fuery MA, Chouairi F, Januzzi JL, Moe GW, Caraballo C, McCullough M, Miller PE, Reinhardt SW, Clark K, Oseran A, Milner A, Pacor J, Kahn PA, Singh A, Ravindra N, Guha A, Vadlamani L, Kulkarni NS, Fiuzat M, Felker GM, O'Connor CM, Ahmad T, Ezekowitz J, Desai NR. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC Heart Fail. 2021 Jul;9(7):497-505. doi: 10.1016/j.jchf.2021.02.011. Epub 2021 May 12."}, {"pmid": "33955231", "type": "DERIVED", "citation": "Daubert MA, Yow E, Barnhart HX, Pina IL, Ahmad T, Leifer E, Cooper L, Desvigne-Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O'Connor CM, Felker GM. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2021 May 18;10(10):e019712. doi: 10.1161/JAHA.120.019712. Epub 2021 May 6."}, {"pmid": "33754794", "type": "DERIVED", "citation": "Parcha V, Patel N, Kalra R, Suri SS, Arora G, Wang TJ, Arora P. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial. J Am Heart Assoc. 2021 Apr 6;10(7):e018689. doi: 10.1161/JAHA.120.018689. Epub 2021 Mar 23."}, {"pmid": "32319999", "type": "DERIVED", "citation": "Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, Whellan DJ, Ahmad T, Adams K, Pina IL, Patel CB, Anstrom KJ, Cooper LS, Mark D, Leifer ES, Felker GM, Januzzi JL, O'Connor CM. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020 Jul 1;5(7):757-764. doi: 10.1001/jamacardio.2020.0640."}, {"pmid": "31466618", "type": "DERIVED", "citation": "Januzzi JL Jr, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Mark DB, Pina IL, Passmore G, Whellan DJ, Cooper LS, Leifer ES, Desvigne-Nickens P, Felker GM, O'Connor CM. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 Sep 3;74(9):1205-1217. doi: 10.1016/j.jacc.2019.06.055."}, {"pmid": "30919549", "type": "DERIVED", "citation": "O'Connor C, Fiuzat M, Mulder H, Coles A, Ahmad T, Ezekowitz JA, Adams KF, Pina IL, Anstrom KJ, Cooper LS, Mark DB, Whellan DJ, Januzzi JL Jr, Leifer ES, Felker GM. Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. Eur J Heart Fail. 2019 Jun;21(6):770-778. doi: 10.1002/ejhf.1450. Epub 2019 Mar 27."}, {"pmid": "30611722", "type": "DERIVED", "citation": "Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, Norris C, Cooper L, Leifer E, Desvigne-Nickens P, Anstrom K, Fiuzat M, Ezekowitz J, Mark DB, O'Connor CM, Januzzi J, Felker GM. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. JACC Heart Fail. 2019 Feb;7(2):158-168. doi: 10.1016/j.jchf.2018.10.014. Epub 2019 Jan 2."}, {"pmid": "30466512", "type": "DERIVED", "citation": "Mark DB, Cowper PA, Anstrom KJ, Sheng S, Daniels MR, Knight JD, Baloch KN, Davidson-Ray L, Fiuzat M, Januzzi JL Jr, Whellan DJ, Pina IL, Ezekowitz JA, Adams KF, Cooper LS, O'Connor CM, Felker GM. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. J Am Coll Cardiol. 2018 Nov 27;72(21):2551-2562. doi: 10.1016/j.jacc.2018.08.2184."}, {"pmid": "28829876", "type": "DERIVED", "citation": "Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL Jr, Mark DB, Pina IL, Passmore G, Whellan DJ, Yang H, Cooper LS, Leifer ES, Desvigne-Nickens P, O'Connor CM. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2017 Aug 22;318(8):713-720. doi: 10.1001/jama.2017.10565."}, {"pmid": "25194287", "type": "DERIVED", "citation": "Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL, Leifer ES, Mark DB, Desvigne-Nickens P, Paynter G, Pina IL, Whellan DJ, O'Connor CM. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart Fail. 2014 Oct;2(5):457-65. doi: 10.1016/j.jchf.2014.05.007. Epub 2014 Sep 3."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "894 participants were randomized", "groups": [{"id": "FG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "FG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "448"}, {"groupId": "FG001", "numSubjects": "446"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "119"}, {"groupId": "FG001", "numSubjects": "114"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "329"}, {"groupId": "FG001", "numSubjects": "332"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "77"}, {"groupId": "FG001", "numSubjects": "66"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "Futility", "reasons": [{"groupId": "FG000", "numSubjects": "197"}, {"groupId": "FG001", "numSubjects": "200"}]}, {"type": "Had VAD, Dialysis or Transplant", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "17"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "BG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "448"}, {"groupId": "BG001", "value": "446"}, {"groupId": "BG002", "value": "894"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.5", "spread": "13.4"}, {"groupId": "BG001", "value": "60.4", "spread": "14.3"}, {"groupId": "BG002", "value": "61.5", "spread": "13.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "147"}, {"groupId": "BG001", "value": "139"}, {"groupId": "BG002", "value": "286"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "301"}, {"groupId": "BG001", "value": "307"}, {"groupId": "BG002", "value": "608"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "58"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "420"}, {"groupId": "BG001", "value": "416"}, {"groupId": "BG002", "value": "836"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "27"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "167"}, {"groupId": "BG002", "value": "322"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "257"}, {"groupId": "BG001", "value": "228"}, {"groupId": "BG002", "value": "485"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "27"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "CV Death or Heart Failure Hospitalization", "description": "Composite of First Heart Failure Hospitalization or Cardiovascular Mortality", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "24 Months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "164"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.88", "pValueComment": "A sample size of 1100 patients was expected to provide approximately 90% power to detect a difference in the primary endpoint with an assumed type I error rate of 0.05, 2-sided. Analysis was adjusted for age, sex, ejection fraction, NT-proBNP and DM.", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.79", "ciUpperLimit": "1.22"}]}, {"type": "SECONDARY", "title": "All-cause Mortality", "description": "All-cause mortality by treatment arm", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "deaths", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.37", "statisticalMethod": "Regression, Cox", "paramType": "Cox Proportional Hazard", "paramValue": "0.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.62", "ciUpperLimit": "1.20"}]}, {"type": "SECONDARY", "title": "Cumulative Morbidity", "description": "Days alive and not hospitalized for CV reasons", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "days", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "616", "lowerLimit": "595", "upperLimit": "637"}, {"groupId": "OG001", "value": "626", "lowerLimit": "605", "upperLimit": "646"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.53", "statisticalMethod": "Bang-Tsiatis Partitioned Estimator", "paramType": "Mean Difference (Net)", "paramValue": "9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20", "ciUpperLimit": "39"}]}, {"type": "SECONDARY", "title": "CV Death", "description": "CV death by treatment arm", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "deaths", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.75", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.65", "ciUpperLimit": "1.37"}]}, {"type": "SECONDARY", "title": "Number of Hospitalizations for First Heart Failure", "description": "First Heart Failure Hospitalization", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "hospitalizations", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "147"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.76", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "1.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.82", "ciUpperLimit": "1.31"}]}, {"type": "SECONDARY", "title": "Number of Hospitalizations for Recurrent Heart Failure", "description": "Recurrent Heart Failure Hospitalization", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "hospitalizations", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "448"}, {"groupId": "OG001", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "277"}, {"groupId": "OG001", "value": "350"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.08", "statisticalMethod": "Anderson-Gill Intensity Model", "paramType": "Hazard Ratio (HR)", "paramValue": "1.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.97", "ciUpperLimit": "1.72"}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Moderate to Severe Depression", "description": "Percentage of patients with moderate to severe depression as measured by the Center for Epidemiologic Studies Depression Scale (CES-D).\n\nCES-D is a 20-item scale measuring general depression. Scores range from 0-60, with higher scores indicating greater general depression. Moderate to severe depression is indicated by a score of 11 or higher.", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, 3,6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "439"}, {"groupId": "OG001", "value": "437"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "439"}, {"groupId": "OG001", "value": "437"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "34.6"}, {"groupId": "OG001", "value": "36.2"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "355"}, {"groupId": "OG001", "value": "345"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26.2"}, {"groupId": "OG001", "value": "27.8"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}, {"groupId": "OG001", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.6"}, {"groupId": "OG001", "value": "27.6"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "254"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.9"}, {"groupId": "OG001", "value": "27.6"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "132"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.4"}, {"groupId": "OG001", "value": "25.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline", "nonInferiorityType": "SUPERIORITY", "pValue": "0.636", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.628", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.586", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.669", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.949", "statisticalMethod": "Mixed Models Analysis"}]}, {"type": "SECONDARY", "title": "Duke Activity Status Index (DASI)", "description": "The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity).", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "443"}, {"groupId": "OG001", "value": "435"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "443"}, {"groupId": "OG001", "value": "435"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.1", "spread": "12.6"}, {"groupId": "OG001", "value": "12.6", "spread": "13.5"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "357"}, {"groupId": "OG001", "value": "349"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.9", "spread": "14.2"}, {"groupId": "OG001", "value": "17.7", "spread": "14.9"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "298"}, {"groupId": "OG001", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.9", "spread": "15.8"}, {"groupId": "OG001", "value": "19.7", "spread": "16.6"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "243"}, {"groupId": "OG001", "value": "260"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.4", "spread": "16.1"}, {"groupId": "OG001", "value": "19.3", "spread": "17.0"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "132"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.6", "spread": "17.8"}, {"groupId": "OG001", "value": "18.2", "spread": "17.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.404", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.880", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.188", "ciUpperLimit": "2.947"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.219", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.478", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.881", "ciUpperLimit": "3.836"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.104", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "2.099", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.433", "ciUpperLimit": "4.630"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.228", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.999", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.253", "ciUpperLimit": "5.250"}]}, {"type": "SECONDARY", "title": "EQ-5D Health Index", "description": "The EQ-5D measures the subjects health status in 5 categories (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and totals them into 1 score, from -0.59 (worst) to 1 (best).", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "439"}, {"groupId": "OG001", "value": "431"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "439"}, {"groupId": "OG001", "value": "431"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.3"}, {"groupId": "OG001", "value": "0.7", "spread": "0.3"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "372"}, {"groupId": "OG001", "value": "358"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.3"}, {"groupId": "OG001", "value": "0.7", "spread": "0.3"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "319"}, {"groupId": "OG001", "value": "321"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.3"}, {"groupId": "OG001", "value": "0.7", "spread": "0.3"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "269"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.3"}, {"groupId": "OG001", "value": "0.7", "spread": "0.3"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "137"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.3"}, {"groupId": "OG001", "value": "0.7", "spread": "0.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.421", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.025", "ciUpperLimit": "0.060"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.239", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.028", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.018", "ciUpperLimit": "0.074"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.402", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.021", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.028", "ciUpperLimit": "0.070"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.780", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.009", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.057", "ciUpperLimit": "0.076"}]}, {"type": "SECONDARY", "title": "EQ-5D Visual Analog Scale", "description": "The EQ-5D VAS records participants self-rated health status on a vertical (0-100) scale with higher scores indicating higher Health-Related Quality of Life, where 0 = worst imaginable health state and 100 = best imaginable health state.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "446"}, {"groupId": "OG001", "value": "445"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.2", "spread": "37.6"}, {"groupId": "OG001", "value": "59.2", "spread": "22.6"}]}]}, {"title": "3 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.3", "spread": "25.9"}, {"groupId": "OG001", "value": "60.2", "spread": "27.8"}]}]}, {"title": "6 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.5", "spread": "26.5"}, {"groupId": "OG001", "value": "61.5", "spread": "25.8"}]}]}, {"title": "12 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.7", "spread": "25.8"}, {"groupId": "OG001", "value": "62.1", "spread": "24.9"}]}]}, {"title": "24 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.9", "spread": "24.0"}, {"groupId": "OG001", "value": "60.8", "spread": "24.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.268", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.131", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.902", "ciUpperLimit": "1.640"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.599", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.069", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.921", "ciUpperLimit": "5.058"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.852", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.389", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.486", "ciUpperLimit": "3.707"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.221", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.343", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.708", "ciUpperLimit": "2.022"}]}, {"type": "SECONDARY", "title": "Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Score", "description": "This KCCQ overall score represents the mean of the following 4 scores: Physical Limitation, Total Symptom, Quality of Life, and Social Limitation. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6,12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "444"}, {"groupId": "OG001", "value": "441"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "444"}, {"groupId": "OG001", "value": "441"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "57.7", "spread": "22.4"}, {"groupId": "OG001", "value": "57.5", "spread": "21.6"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "384"}, {"groupId": "OG001", "value": "373"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "69.2", "spread": "22.8"}, {"groupId": "OG001", "value": "68.8", "spread": "22.6"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}, {"groupId": "OG001", "value": "332"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "70.1", "spread": "22.2"}, {"groupId": "OG001", "value": "70.4", "spread": "21.8"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "270"}, {"groupId": "OG001", "value": "279"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "70.3", "spread": "21.9"}, {"groupId": "OG001", "value": "68.4", "spread": "24.3"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.6", "spread": "24.4"}, {"groupId": "OG001", "value": "70.2", "spread": "22.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.615", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.816", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.999", "ciUpperLimit": "2.367"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.878", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.252", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.977", "ciUpperLimit": "3.482"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.441", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.406", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.989", "ciUpperLimit": "2.178"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.653", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.091", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.673", "ciUpperLimit": "5.856"}]}, {"type": "SECONDARY", "title": "Short Form-36 (SF-36) General Health Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "436"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "436"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "48.4", "spread": "11.1"}, {"groupId": "OG001", "value": "48.6", "spread": "10.7"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "348"}, {"groupId": "OG001", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "51.1", "spread": "12.6"}, {"groupId": "OG001", "value": "50.0", "spread": "12.9"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "294"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "50.5", "spread": "12.7"}, {"groupId": "OG001", "value": "49.9", "spread": "12.9"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "238"}, {"groupId": "OG001", "value": "250"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "51.0", "spread": "12.2"}, {"groupId": "OG001", "value": "50.8", "spread": "12.6"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "129"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "48.8", "spread": "12.8"}, {"groupId": "OG001", "value": "50.4", "spread": "11.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.199", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.226", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.097", "ciUpperLimit": "0.645"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.465", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.742", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.735", "ciUpperLimit": "1.250"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.943", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.074", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.119", "ciUpperLimit": "1.970"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.294", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.478", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.286", "ciUpperLimit": "4.241"}]}, {"type": "SECONDARY", "title": "Short Form-36 (SF-36) Mental Health Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "438"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "438"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "69.7", "spread": "20.4"}, {"groupId": "OG001", "value": "69.8", "spread": "20.9"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "352"}, {"groupId": "OG001", "value": "339"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "77.6", "spread": "19.9"}, {"groupId": "OG001", "value": "76.1", "spread": "21.5"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "291"}, {"groupId": "OG001", "value": "298"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "77.7", "spread": "20.5"}, {"groupId": "OG001", "value": "77.1", "spread": "21.3"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "250"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "77.5", "spread": "20.3"}, {"groupId": "OG001", "value": "76.2", "spread": "22.2"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "129"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "79.6", "spread": "17.6"}, {"groupId": "OG001", "value": "76.6", "spread": "22.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.294", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.579", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.527", "ciUpperLimit": "1.369"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.555", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.946", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.096", "ciUpperLimit": "2.203"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.643", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.798", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.178", "ciUpperLimit": "2.583"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.757", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.647", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.767", "ciUpperLimit": "3.472"}]}, {"type": "SECONDARY", "title": "Short Form-36 (SF-36) Social Functioning Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "440"}, {"groupId": "OG001", "value": "437"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.2", "spread": "32.7"}, {"groupId": "OG001", "value": "64.8", "spread": "30.1"}]}]}, {"title": "3 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.4", "spread": "30.8"}, {"groupId": "OG001", "value": "74.9", "spread": "31.8"}]}]}, {"title": "6 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.0", "spread": "32.3"}, {"groupId": "OG001", "value": "75.0", "spread": "32.1"}]}]}, {"title": "12 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.4", "spread": "30.9"}, {"groupId": "OG001", "value": "74.5", "spread": "31.5"}]}]}, {"title": "24 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.7", "spread": "30.3"}, {"groupId": "OG001", "value": "77.2", "spread": "31.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.837", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.484", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.102", "ciUpperLimit": "4.133"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.288", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.693", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.662", "ciUpperLimit": "2.276"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.567", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.539", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.810", "ciUpperLimit": "3.732"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.475", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "2.512", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.394", "ciUpperLimit": "9.419"}]}, {"type": "SECONDARY", "title": "Short Form-36 (SF-36) Physiological Functioning Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "442"}, {"groupId": "OG001", "value": "433"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "442"}, {"groupId": "OG001", "value": "433"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "30.6", "spread": "32.1"}, {"groupId": "OG001", "value": "31.5", "spread": "31.2"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "355"}, {"groupId": "OG001", "value": "343"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.5", "spread": "35.9"}, {"groupId": "OG001", "value": "43.3", "spread": "37.5"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}, {"groupId": "OG001", "value": "302"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.4", "spread": "37.4"}, {"groupId": "OG001", "value": "45.6", "spread": "37.2"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "238"}, {"groupId": "OG001", "value": "253"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "41.9", "spread": "38.2"}, {"groupId": "OG001", "value": "47.4", "spread": "37.1"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "129"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "47.0", "spread": "38.1"}, {"groupId": "OG001", "value": "43.2", "spread": "38.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.696", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.057", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.250", "ciUpperLimit": "6.364"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 months", "nonInferiorityType": "SUPERIORITY", "pValue": "0.497", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.966", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.715", "ciUpperLimit": "7.647"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.035", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "6.564", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.456", "ciUpperLimit": "12.673"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.488", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "2.857", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.247", "ciUpperLimit": "10.961"}]}, {"type": "SECONDARY", "title": "Short Form-36 (SF-36) Vitality Subscale", "description": "SF-36 measures perceived Quality of Life. The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.", "populationDescription": "\"Number of participants analyzed\" is the number of participants who completed the questionnaire", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 3, 6, 12 and 24 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}, {"id": "OG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "438"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "438"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.9", "spread": "22.5"}, {"groupId": "OG001", "value": "44.3", "spread": "22.3"}]}]}, {"title": "3 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "353"}, {"groupId": "OG001", "value": "339"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "54.5", "spread": "23.6"}, {"groupId": "OG001", "value": "54.6", "spread": "23.6"}]}]}, {"title": "6 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "291"}, {"groupId": "OG001", "value": "296"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55.1", "spread": "24.6"}, {"groupId": "OG001", "value": "55.8", "spread": "23.9"}]}]}, {"title": "12 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "234"}, {"groupId": "OG001", "value": "250"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "54.4", "spread": "23.6"}, {"groupId": "OG001", "value": "55.2", "spread": "24.3"}]}]}, {"title": "24 month", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "129"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "57.9", "spread": "24.8"}, {"groupId": "OG001", "value": "55.9", "spread": "24.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "3 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.992", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.383", "ciUpperLimit": "3.417"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "6 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.882", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.280", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.409", "ciUpperLimit": "3.969"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "12 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.647", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.904", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.973", "ciUpperLimit": "4.782"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "24 month", "nonInferiorityType": "SUPERIORITY", "pValue": "0.903", "pValueComment": "Adjusted P-value", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.322", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.894", "ciUpperLimit": "5.538"}]}, {"type": "SECONDARY", "title": "Resource Utilization", "description": "Observed Resource Use", "populationDescription": "US Patients in Economics Substudy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "events", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}, {"id": "OG001", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "362"}]}], "classes": [{"title": "Number of Hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.93", "spread": "2.80"}, {"groupId": "OG001", "value": "1.83", "spread": "2.36"}]}]}, {"title": "Number of ER only events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "1.28"}, {"groupId": "OG001", "value": "0.56", "spread": "1.29"}]}]}, {"title": "Number of Rehab facilities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.35"}, {"groupId": "OG001", "value": "0.06", "spread": "0.25"}]}]}, {"title": "Total admissions", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.56", "spread": "3.64"}, {"groupId": "OG001", "value": "2.45", "spread": "3.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Hospitalizations", "nonInferiorityType": "SUPERIORITY", "pValue": "0.74", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "ER only events", "nonInferiorityType": "SUPERIORITY", "pValue": "0.45", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Rehab facilities", "nonInferiorityType": "SUPERIORITY", "pValue": "0.67", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Total admissions", "nonInferiorityType": "SUPERIORITY", "pValue": "0.47", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Resource Utilization Cost", "description": "Observed Hospital-Based Cost.", "populationDescription": "US Patients with billing data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "2016 US dollars", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP"}, {"id": "OG001", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "363"}, {"groupId": "OG001", "value": "350"}]}], "classes": [{"title": "Hospital Costs", "categories": [{"measurements": [{"groupId": "OG000", "value": "47,055", "spread": "92,270"}, {"groupId": "OG001", "value": "34,396", "spread": "60,842"}]}]}, {"title": "Physician Fees", "categories": [{"measurements": [{"groupId": "OG000", "value": "2,291", "spread": "4,128"}, {"groupId": "OG001", "value": "1,761", "spread": "2,601"}]}]}, {"title": "Total Cost", "categories": [{"measurements": [{"groupId": "OG000", "value": "49,346", "spread": "96,082"}, {"groupId": "OG001", "value": "36,157", "spread": "63,110"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Hospital Costs", "nonInferiorityType": "SUPERIORITY", "pValue": "0.88", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Physician Fees", "nonInferiorityType": "SUPERIORITY", "pValue": "0.69", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000"], "groupDescription": "Total Cost", "nonInferiorityType": "SUPERIORITY", "pValue": "0.88", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Randomization through completion of the final study visit at 24 months", "description": "SAEs and AEs of Interest that occur from randomization through completion of the final study visit will be reported.", "eventGroups": [{"id": "EG000", "title": "Usual Care", "description": "Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.\n\nUsual Care: Usual Care", "deathsNumAffected": 77, "deathsNumAtRisk": 448, "seriousNumAffected": 36, "seriousNumAtRisk": 448, "otherNumAffected": 157, "otherNumAtRisk": 448}, {"id": "EG001", "title": "Biomarker-Guided Care", "description": "Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.\n\nBiomarker-guided care NT-proBNP: Device: NT-proBNP", "deathsNumAffected": 66, "deathsNumAtRisk": 446, "seriousNumAffected": 51, "seriousNumAtRisk": 446, "otherNumAffected": 178, "otherNumAtRisk": 446}], "seriousEvents": [{"term": "Symptomatic Hypotension", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 446}]}, {"term": "Symptomatic Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 446}]}, {"term": "Hyperkalemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 446}]}, {"term": "Worsening renal function", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 446}]}, {"term": "Other Adverse Events", "organSystem": "Investigations", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Other Adverse Events", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 446}]}], "otherEvents": [{"term": "Symptomatic Hypotension", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 37, "numAtRisk": 446}]}, {"term": "Symptomatic Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 446}]}, {"term": "Hyperkalemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 446}]}, {"term": "Worsening renal function", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 83, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 91, "numAtRisk": 446}]}, {"term": "Other Adverse Events", "organSystem": "Investigations", "sourceVocabulary": "Protocol defined", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Other Adverse Events", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 448}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 446}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "G. Michael Felker, M.D.", "organization": "Duke University Health System", "email": "michael.felker@duke.edu", "phone": "919-668-8919"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}